Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.80 |
| ▸ | RXRA | P19793 | 1/20 | 0.69 |
| ▸ | RXRB | P28702 | 1/20 | 0.69 |
| ▸ | MAOB | P27338 | 9/20 | 0.67 |
| ▸ | CA12 | O43570 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 1/20 | 0.67 |
| ▸ | CA7 | P43166 | 1/20 | 0.67 |
| ▸ | CA9 | Q16790 | 1/20 | 0.67 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.65 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 6/20 | 0.59 |
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618116 | 0.91 | APP (0.69) | APPRXRARXRBMAOBCA12 | |
| SCHEMBL11601389 | 0.91 | APP (0.69) | APPRXRARXRBMAOBCA12 | |
| SCHEMBL13929696 | 0.89 | APP (0.67) | APPRXRARXRBMAOBCA12 | |
| SCHEMBL15271017 | 0.89 | APP (1.00) | APPRXRARXRBMAOBCA12 | |
| SCHEMBL2270908 | 0.89 | MAOB (0.69) | APPRXRARXRBMAOBCA12 | |
| SCHEMBL18429678 | 0.89 | MAOB (0.69) | APPRXRARXRBMAOBCA12 | |
| SCHEMBL14154468 | 0.89 | APP (0.67) | APPRXRARXRBMAOBCA12 | |
| SCHEMBL21221839 | 0.89 | MAOB (0.67) | APPRXRARXRBMAOBCA12 | |
| SCHEMBL21568939 | 0.89 | MAOB (0.67) | APPRXRARXRBMAOBCA12 | |
| SCHEMBL16295189 | 0.89 | APP (0.67) | APPRXRARXRBMAOBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961756-B1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE & TECH AGENCY (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-8853424-B2 | Protein cross-linking inhibitor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8017809-B2 | Bisboron compound | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-09-01 | — | — | US | disclosed |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1961756-A1 | NOVEL BISBORON COMPOUND | Japan Science and Technology Agency (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212919-A1 | PROTEIN CROSS-LINKING INHIBITOR | BAZ2B, PRMT1, BRIX1 | APP 3361/4885RXRA 1994/4885RXRB 883/4885 |
| US-20100087645-A1 | NOVEL BISBORON COMPOUND | KCNMB4, CA2, NR0B2 | APP 3735/4885RXRA 1400/4885RXRB 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.